Analyst Price Targets — ODD
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 3, 2026 6:58 pm | — | Evercore ISI | $15.00 | $10.25 | TheFly | Oddity price target lowered to $15 from $23 at Evercore ISI |
| June 3, 2026 1:10 pm | — | Goldman Sachs | $8.00 | $10.32 | TheFly | Goldman downgrades Oddity to Sell on challenged path forward |
| June 3, 2026 12:20 pm | Dara Mohsenian | Morgan Stanley | $10.00 | $10.06 | TheFly | Oddity price target lowered to $10 from $16 at Morgan Stanley |
| June 3, 2026 10:04 am | — | Barclays | $8.00 | $9.84 | TheFly | Oddity price target lowered to $8 from $13 at Barclays |
| June 2, 2026 7:57 pm | Brian Tanquilut | Jefferies | $10.25 | $9.84 | StreetInsider | Oddity Tech Ltd (ODD) PT Lowered to $10.25 at Jefferies |
| June 2, 2026 5:06 pm | Youssef Squali | Truist Financial | $12.00 | $9.62 | TheFly | Oddity price target lowered to $12 from $18 at Truist |
| April 28, 2026 7:08 pm | — | Jefferies | $14.00 | $15.41 | TheFly | Oddity price target lowered to $14 from $18 at Jefferies |
| March 27, 2026 11:03 am | Bonnie Herzog | Goldman Sachs | $16.00 | $13.22 | TheFly | Oddity price target lowered to $16 from $20 at Goldman Sachs |
| February 25, 2026 8:45 pm | Bonnie Herzog | Goldman Sachs | $20.00 | $14.74 | StreetInsider | Oddity Tech Ltd (ODD) PT Lowered to $20 at Goldman Sachs |
| February 25, 2026 6:07 pm | — | Truist Financial | $18.00 | $14.79 | TheFly | Oddity downgraded to Hold at Truist on poor visibility |
Latest News for ODD
Fosun International Garners Five Awards from Corporate Governance Asia PR Newswire HONG KONG, July 2, 2026
REX Shares ("REX") and Tuttle Capital Management ("TCM") today announce that listed options are now available on the T-REX 2X Long SpaceX Daily Target ETF (NYS
Oddity Tech is downgraded from buy to hold due to unresolved customer acquisition cost headwinds and weak first-order growth. Q1 2026 revenue declined 26% y/y, with first orders down ~50% and margins deteriorating; Q2 guidance suggests continued revenue contraction. The investment thesis now hinges on whether CPA normalization is temporary or structural, as elevated CPA undermines the core acquisition engine.
Lundbeck to present new patient data on neuroendocrine and neuroimmunology programs at ENDO 2026 PR Newswire VAL
Oddity is getting hit with another massive post-earnings sell-off, and the stock is down roughly 87% over the last year.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ODD.
U.S. House Trading
No House trades found for ODD.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.